TrialTrials2017

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Peter Saunders et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.